Surface Oncology: Jumps after cancer drug gets FDA 'fast track' status

Surface Oncology

11/11/2020 13:42

** Shares of drug developer  SURF.O  rise 9.8% to $9.96
premarket; among top pct. gainers across U.S. exchanges
    ** Co's liver cancer treatment, SRF388, receives "fast
track" status from FDA  urn:newsml:reuters.com:*:nGNXQBJ7Z
    ** SURF is currently enrolling patients with advanced solid
tumors in an early-stage trial for SRF388 
    ** Street Insider reported in Oct. that SURF was exploring a
potential sale after GlaxoSmithKline Plc's  GSK.L  takeover bid
 urn:newsml:reuters.com:*:nL4N2H33A6
    ** Stock up 382.5% this year, as of last close

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))